I agree that this site is using cookies. You can find further informations here.
X
Belada, D.
227  results:
Search for persons X
?
1

HTA73 Cured and Invisible? Rationale for Mixture-Cure Model..:

Novák, J ; Vodicka, P ; Janikova, A...
Value in Health.  27 (2024)  6 - p. S257 , 2024
Link: https://doi.org/10.1016/..
 
?
2

IMMUNE CONTEXTURE ANALYSIS IN POLARIX SUGGESTS RESPONSE TO ..:

Morschhauser, F. ; Hatzi, K. ; Lenz, G....
Hematological Oncology.  41 (2023)  S2 - p. 223-225 , 2023
Link: https://doi.org/10.1002/..
 
?
3

EPCORITAMAB WITH RITUXIMAB + LENALIDOMIDE (R2) PROVIDES DUR..:

Belada, D. ; Falchi, L. ; Leppä, S....
Hematological Oncology.  41 (2023)  S2 - p. 125-127 , 2023
Link: https://doi.org/10.1002/..
 
?
4

HOW WE ARE SUCCESSFUL IN THERAPY OF T‐CELL LYMPHOMA PATIENT..:

Janikova, A. ; Klanova, M. ; Belada, D....
Hematological Oncology.  41 (2023)  S2 - p. 762-762 , 2023
Link: https://doi.org/10.1002/..
 
?
5

BRENTUXIMAB VEDOTIN IN COMBINATION WITH CHEMOTHERAPY IN PAT..:

Klanova, M. ; Sykorova, A. ; Janikova, A....
Hematological Oncology.  41 (2023)  S2 - p. 763-764 , 2023
Link: https://doi.org/10.1002/..
 
?
6

HIGH COMPLETE METABOLIC RESPONSE RATES WITH EPCORITAMAB + R..:

Falchi, L. ; Clausen, M. R. ; Offner, F....
Hematological Oncology.  41 (2023)  S2 - p. 207-208 , 2023
Link: https://doi.org/10.1002/..
 
?
7

ANALYSIS OF PATIENTS IN THE FIRST RELAPSE OR PROGRESSION OF..:

Janikova, A. ; Belada, D. ; Klanova, M....
Hematological Oncology.  41 (2023)  S2 - p. 764-764 , 2023
Link: https://doi.org/10.1002/..
 
?
8

OUTCOMES OF THE TREATMENT AFTER ANTI‐CD19 CAR‐T THERAPY FAI..:

Sýkorová, A. ; Polgárová, K. ; Folber, F....
Hematological Oncology.  41 (2023)  S2 - p. 792-793 , 2023
Link: https://doi.org/10.1002/..
 
?
9

P1135: SUBCUTANEOUS EPCORITAMAB IN COMBINATION WITH RITXUIM..:

Belada, D. ; Leppä, S. ; Wahlin, B. E....
HemaSphere.  6 (2022)  - p. 1025-1026 , 2022
Link: https://doi.org/10.1097/..
 
?
10

Clinical value of ALK and CD30 expression in mature systemi..:

Janikova, A. ; Michalka, J. ; Chloupkova, R....
Annals of Hematology.  101 (2022)  4 - p. 789-798 , 2022
Link: https://doi.org/10.1007/..
 
?
11

P1161: ASPEN: LONG-TERM FOLLOW-UP RESULTS OF A PHASE 3 RAND..:

Dimopoulos, M. ; Opat, S. ; D'Sa, S....
HemaSphere.  6 (2022)  - p. 1048-1049 , 2022
Link: https://doi.org/10.1097/..
 
?
12

Cryopreservation techniques in manufacturing, transport and..:

Jandová, M. ; Stacey, G.N. ; Lánská, M....
Cryobiology.  109 (2022)  - p. 18-19 , 2022
Link: https://doi.org/10.1016/..
 
?
13

PB2110: PHARMACOKINETICS AND PHARMACODYNAMICS IN FIRST-MIND..:

Belada, D. ; Kopeckova, K. ; Bergua Burgues, J. M....
HemaSphere.  6 (2022)  - p. 1981-1982 , 2022
Link: https://doi.org/10.1097/..
 
?
14

S209: PRIMARY RESULTS FROM THE PHASE 3 SHINE STUDY OF IBRUT..:

Wang, M. L. ; Jurczak, W. ; Jerkeman, M....
HemaSphere.  6 (2022)  - p. 110-111 , 2022
Link: https://doi.org/10.1097/..
 
?
15

The ECHELON-2 Trial: 5-year results of a randomized, phase ..:

Horwitz, S. ; O'Connor, O.A. ; Pro, B....
Annals of Oncology.  33 (2022)  3 - p. 288-298 , 2022
Link: https://doi.org/10.1016/..
 
1-15